Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

Diabetes, Obesity and Metabolism

Volumn 13, Issue 2, 2011, Pages 185-188

  Lindblad, U ^a,b   Lindberg, G ^c,d   Mansson N O ^c   Ranstam, J ^d,e   Tyrberg, M ^c,f   Jansson, S ^g   Lindwall, K ^d   Svardh M ^c,d   Kindmalm, L ^b,h   Melander, A ^c,d,i  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Skaraborgs Institutet   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Network for Pharmacoepidemiology Foundation   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f HELSINGBORG HOSPITAL   (Sweden)

^g ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^h RandD Center Skaraborg Primary Care   (Sweden)

ⁱ Skövde ^*  (Sweden)

Author keywords

IFG; Prevention; Primary care; Randomized trial; Sulphonylurea; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLUCOSE; PLACEBO;

ADULT; AGED; CLINICAL EFFECTIVENESS; DIET RESTRICTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; TREATMENT OUTCOME;

EID: 78650662421     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01331.x     Document Type: Letter

References (12)

1. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
2. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
4. Knowler WC, Hamman RF, Edelstein SL et al. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2005; 54: 1150-1156.
5. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
6. Sartor G, Scherstén B, Carlström S, Melander A, Nordén Å, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41-49.
7. Stenman S, Melander A, Groop P-H, Groop L. What is the benefit of increasing the sulphonylurea dose? Ann Int Med 1993; 118: 169-172.
8. Lindblad U, Lindwall K, Sjöstrand Å, Ranstam J, Melander A. The NEPI antidiabetes study (NANSY): 1. short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabet Obes Metab 2001; 3: 443-51.
9. Eckerbom S, Bergqvist Y, Jeppsson JO. Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem 1994; 31: 355-360.
10. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39: 578-582.
11. Kjems LL, Roder ME, Dinesen B, Hartling SG, Jorgensen PN, Binder C. Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 1993; 39: 2146-2150.
12. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000; 46: 934-938.